Thirteen of the 42 teams participating in RBPC 2024 walked away with investment funding. Photo courteys of Rice University

For the 24th year, the Rice Alliance for Technology and Entrepreneurship hosted its Rice Business Plan Competition, facilitating over $1.5 million in investment and cash prizes to the top teams.

The 42 startups competing this year, which were announced earlier this year and included teams from around the world, participated in the three-day event that culminated in a reception on Saturday, April 6. The companies were divided into five categories: Energy, Cleantech and Sustainability; Hard Tech; Life Sciences and Healthcare Solutions; Digital Enterprise; Consumer Products and Services.

“We award the competitors $1 million in prizes, prizes that serve as foundational capital to launch their startup,” RBPC Director Catherine Santamaria says at the awards gala. “That’s a large number of prizes, but the biggest thing our startups leave with is a feeling of generosity and community from this room. This community is always ready and willing to help our founders and support our vision for the competition by investing time, money and resources in these student innovators.”

While all participating teams received $950 for being selected, several teams walked away with thousands in funding, cash, and in-kind prizes. Here's which companies won big.

MesaQuantum, Harvard University — $335,000​

MesaQuantum is developing accurate and precise chip-scale clocks. While not named a finalist, the company secured the most amount of funding across a few prizes:

  • $250,000 OWL Investment Prizes
  • $60,000 nCourage Courageous Women Entrepreneur Investment Prize
  • $25,000 Jacobs, Intuitive Machines and WRX Companies Rising Stars Space Technology and Commercial Aerospace Cash Prize

Protein Pints, Michigan State University — $251,000

The big winner of the night was Protein Pints, a high-protein, low-sugar, ice cream product from Michigan State University. Not only did the company win first place and the $150,000 GOOSE Capital Investment Grand Prize, as decided by the more than 350 judges, but it won a few other investment prizes, including:

  • $100,000 The Indus Entrepreneurs (TiE) Texas Angels Investment Prize — Protein Pints, Michigan State University
  • The Eagle Investors Prize
  • $1,000 Anbarci Family Company Showcase Prize
  • Mercury Elevator Pitch Competition Prize (Best in Consumer Products)
  • An invitation to Entrepreneur Magazine's elevator pitch show

Osphim, RWTH Aachen University —$201,000

Osphim, a data acquisition and monitoring platform from Germany, won these prizes despite not being named a finalist:

  • $200,000 Goose Capital Investment Prize
  • $1,000 Anbarci Family Company Showcase Prize
  • Mercury Elevator Pitch Competition Prize (Best in Digital)

Somnair, Johns Hopkins University — $200,000

Taking second place and a $100,000 from David Anderson, Jon Finger, Anderson Family Fund, Finger Interests, Greg Novak and Tracy Druce was Somnair is a novel non-invasive neurostimulation device for the treatment of obstructive sleep apnea. The company also won:

  • $100,000 Houston Angel Network Investment Prize
  • Mercury Elevator Pitch Competition Prize (Best in Life Science)
  • An invitation to Texas Medical Center's Accelerator Bootcamp
  • An invitation to Entrepreneur Magazine's elevator pitch show

Icorium Engineering Company, University of Kansas — $171,000

Icorium Engineering Company — a chemical engineering startup developing technologies to make sustainable, circular economies a reality for refrigerants and other complex chemical mixtures — won fifth place and a $5,000 prize sponsored by Norton Rose Fulbright, EY, Chevron Technology Ventures and Shell Ventures, as well as:

  • $100,000 OWL Investment Prizes
  • $40,000 nCourage Courageous Women Entrepreneur Investment Prize
  • $25,000 from Finger Interests, the Anderson Family Fund at the Greater Houston Community Foundation, Greg Novak and Tracy Druce
  • $1,000 Anbarci Family Company Showcase Prize
  • Mercury Elevator Pitch Competition Prize (Best in Energy, Sustainability)
  • An invitation to Entrepreneur Magazine's elevator pitch show

Informuta, Tulane University — $70,000

Informuta's proprietary technology leverages DNA sequencing to predict if bacteria will respond to different antibiotics or, for the very first time, develop future resistance thus causing treatment failure. The company won fourth place and a $5,000 prize sponsored by Norton Rose Fulbright, EY, Chevron Technology Ventures and Shell Ventures.

  • $40,000 Pearland EDC Spirit of Entrepreneurship Cash Prize
  • $25,000 from Finger Interests, the Anderson Family Fund at the Greater Houston Community Foundation, Greg Novak and Tracy Druce

EndoShunt Medical, Harvard University — $55,000

EndoShunt created a rapid, targeted blood flow control device to be use in emergency or trauma settings. The company won sixth place and the $5,000 prize, sponsored by Norton Rose Fulbright, EY, Chevron Technology Ventures and Shell Ventures, as well as:

  • $25,000 Southwest National Pediatric Device Consortium Pediatric Device Cash Prize
  • $25,000 from Finger Interests, the Anderson Family Fund at the Greater Houston Community Foundation, Greg Novak and Tracy Druce

Power2Polymers, RWTH Aachen University —$50,000

Tackling the challenge of forever chemicals, Power2Polymers is creating safe alternatives free of forever chemicals. The German company took third place and the $50,000 investment sponsored by Finger Interests, the Anderson Family Fund at the Greater Houston Community Foundation, Greg Novak and Tracy Druce. The company also won the Mercury Elevator Pitch Competition Prize (Best Overall).

D.Sole, Carnegie Mellon University — $30,000

D. Sole won the wild card ticket to the finals and took seventh place. The company is advancing the development of remote patient monitoring in podiatry with foot insoles designed for the early detection and monitoring of diabetic foot complications, such as ulcers and deformities. They also won $30,000 from Finger Interests, the Anderson Family Fund at the Greater Houston Community Foundation, Greg Novak and Tracy Druce.

Other prizes:

  • $25,000 New Climate Ventures Sustainable Investment Prize went to Oxylus Energy from Yale University
  • $25,000 Dream Big Ventures Latino Entrepreneur Investment Prize went to Dendritic Health AI from Northwestern University
  • $25,000 NOV Energy Technology Innovation Cash Prize went to LiQuidium from the University of Houston
  • $25,000 Urban Capital Network Diversity Investment Prize in Partnership with South Loop Venture Investment Prize went to TouchStone from University of California, Berkeley

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.